Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.64 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | F3 | P13726 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734093 | 0.89 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30091870 | 0.88 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL210160 | 0.87 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL8090967 | 0.86 | HDAC1 (0.65) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL23997305 | 0.85 | HDAC1 (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30336954 | 0.85 | HDAC1 (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL13110746 | 0.85 | HDAC1 (0.64) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30091837 | 0.84 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL1436302 | 0.82 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2412920 | 0.82 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| WO-2013005049-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040059138-A1 | Dihydropyrancarboxamides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC1 3/4885HDAC2 2/4885HDAC3 5/4885 |
| US-20040059138-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | HDAC1 44/4885HDAC2 237/4885HDAC3 159/4885 |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | HDAC1 67/4885HDAC2 295/4885HDAC3 188/4885 |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC1 3/4885HDAC2 2/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.